الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 204 |  |  |
| | | from | 204 | | |
Abstract
Summary Hepatitis C is an infectious disease caused by hepatitis C virus (HCV) which mainly attacks the liver cells.
Near eighty percent of patients develop CHC that after many years may lead to cirrhosis or liver cancer. Egypt has the highest prevalence rate of HCV in the world. About 14.7% of the Egyptian people have HCV antibodies and 9.8% have an active infection.
In Egypt, The death rate due to liver disease about 40,000 each year (near 10% of all deaths). It is the second after the cardiac diseases.
With the ultimate goal of achieving a more potent strategy to control transmission of HCV in Egypt, The Ministry of Health has set up 32 specialized centers for the nationwide therapy of HCV infection.
Standard treatment for chronic hepatitis C infection was pegylated-interferon (Peg IFN) and ribavirin (RBV).
New era for management of chronic HCV using direct antiviral agents (DAAs) started in 2013.
135
The aim of this study is to compare between the clinical outcome of Simeprevir plus Sofosbuvir regimen and Daclatasvir plus Sofosbuvir regimen in the management of Treatment-naïve chronic Hepatitis C Egyptian patients with compensated cirrhosis and non-cirrhotic patients as regards to sustained virological response (SVR) at the end of treatment and 12 weeks after the end of treatment and the clinical data till the end of the treatment.
This study has been conducted at Viral Hepatitis Unit – Ahmed Maher Teaching Hospital – National committee for the control of viral hepatitis (NCCVH) during the period from June 2015 to November 2016.
The study included 400 Egyptian treatment-naïve chronic hepatitis C patients, who divided into 2 groups. group 1 received sofosbuvir plus simeprevir regimen and group 2 received sofosbuvir plus daclatasvir regimen. Each group was subdivided into 90 patients with compensated cirrhosis (group a) and 110 patients without cirrhosis (group b).